Arthodar
(Diacerein)Phase 3Small molecule
Diacerein is used to treat osteoarthritis pain and slow down joint damage progression. It helps reduce inflammation and pain in joints affected by osteoarthritis.[1] Arthodar is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Arthodar is one of 155 small molecule programs targeting Rheumatic Disease. It is currently in Phase 3.
4
Indications
19
Total Trials
3
Active Trials
154
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
100 competitors in Liver Disease
#DrugCompanyPhaseTrials
1Lorbrena
PfizerApproved
Resotran
TakedaApproved
Exjade
NovartisApproved
Calciferol
Jazz PharmaceuticalsApproved
Alecensa
RocheApproved
Mektovi
PfizerApproved
Elunate
TakedaApproved
Vanflyta
Daiichi SankyoApproved
Tabrecta
NovartisApproved
Brintellix
TakedaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoarthritis5 trials
Diacerein as Adjuvant to Diclofenac Sodium in Indian Patients of Osteoarthritis (OA) Knee
Completed·—·Phase 4·NCT01120015·84 enrolled
Metformin2 trials
Rheumatoid Arthritis1 trial
9 more indications
Type 2 Diabetes1 trial
Arthritis1 trial
Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
Completed·—··NCT04351100·34 enrolled
Inflammatory Cytokines1 trial
Psoriasis Vulgaris1 trial
Topical Diacerein in Psoriasis Vulgaris
Not yet recruiting·—·Phase 4·NCT07352306·60 enrolled
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diacerein. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AANS Pharma